Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis.
Magnetic resonance scans of 74 patients with multiple sclerosis participating in a controlled trial were compared 6 months before and at the end of a 24-32 months-treatment period with either Cyclosporin A (n = 31) or Azathioprine (n = 43). Both qualitative rating and computation of lesion volume showed deterioration in more than 40% of the patients, while by clinical criteria only 10-30% were worse. No significant difference was noted when the two treatment groups were compared. If careful repositioning and standardized image parameters are used, MRI is an indispensable tool for the objective determination of disease progression in MS although it cannot replace clinical examination.
D001379:Azathioprine / Q000627:therapeutic use*; D001921:Brain / Q000473:pathology*; D002986:Clinical Trials as Topic; D003524:Cyclosporins / Q000627:therapeutic use*; D006801:Humans; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy; D013997:Time Factors
D003524:Cyclosporins; D001379:Azathioprine